Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001104659-25-057296
Filing Date
2025-06-06
Accepted
2025-06-06 16:01:59
Documents
15
Effectiveness Date
2025-06-06

Document Format Files

Seq Description Document Type Size
1 FORM S-8 tm2517084d1_s8.htm S-8 42611
2 EXHIBIT 5.1 tm2517084d1_ex5-1.htm EX-5.1 6866
3 EXHIBIT 23.1 tm2517084d1_ex23-1.htm EX-23.1 2169
4 EX-FILING FEES tm2517084d1_ex-filingfees.htm   iXBRL EX-FILING FEES 12405
5 GRAPHIC tm2517084d1_ex5-1img001.jpg GRAPHIC 5405
  Complete submission text file 0001104659-25-057296.txt   186835

Data Files

Seq Description Document Type Size
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2517084d1_ex-filingfees_htm.xml XML 4473
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-287839 | Film No.: 251030450
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)